CN1943582A - Foscarnet sodium composition - Google Patents
Foscarnet sodium composition Download PDFInfo
- Publication number
- CN1943582A CN1943582A CN 200610097281 CN200610097281A CN1943582A CN 1943582 A CN1943582 A CN 1943582A CN 200610097281 CN200610097281 CN 200610097281 CN 200610097281 A CN200610097281 A CN 200610097281A CN 1943582 A CN1943582 A CN 1943582A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- foscarnet sodium
- balance
- group
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 title claims abstract description 35
- 229960000848 foscarnet sodium Drugs 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 208000012639 Balance disease Diseases 0.000 claims abstract description 18
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 18
- 230000001684 chronic effect Effects 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000726445 Viroids Species 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 53
- 108090000978 Interleukin-4 Proteins 0.000 description 19
- 102100037850 Interferon gamma Human genes 0.000 description 15
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 229940108452 foscavir Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101001044455 Rattus norvegicus Interferon gamma Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- -1 phosphonium mesitoyl formic acid trisodium hexahydrate Chemical compound 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a new clinical uses for treatment of Th1/Th2 balance disorder by medicine composition wherein foscarnet sodium as active component, particularly use for Th1/Th2 balance disorder caused by in treatment of hepatitis b virus.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to the foscarnet sodium is the Th1/Th2 balance disorder that purposes, the especially hepatitis B virus of medicine composite for curing Th1/Th2 balance disorder of active component causes.
Background technology
Clinical research at present shows that the disorder of Th1/Th2 balance is the main mechanism that causes the chronic delay of multiple disease, especially in the acute inflammation of the specific internal organs that each viroid causes lapses to chronic inflammatory disease, has played the part of the key player.Therefore the disorder of Th1/Th2 balance is the focus of present chronic viral inflammation research.
Helper T lymphocyte be secretion produce cytokine main cell it, be divided into two subgroups of Th1 and Th2, Th1 subgroup secretion of gamma-IFN, IL-2, LT-α etc. mainly promote the immunoreation of body cell mediation, help virus sweep; Th2 subgroup secretion IL-4, IL-5, IL-6 etc. mainly promote humoral immune reaction.Therefore, the Th1/Th2 balance has very important significance to keeping normal immunologic function.Cause the reason of Th1/Th2 balance disorder to have multiple possibility, think it mainly is at present because all kinds of viral infection cause as hepatitis B virus (HBV), hepatitis C virus (HCV), HIV (human immunodeficiency virus) (HIV), cytomegalovirus (CMV), herpes simplex virus (HSV), change of coxsackie b virus (CVB) etc.
In recent years discover that the disorder of Th1/Th2 function balance mainly shows as the Th1 hypofunction and the Th2 hyperfunctioning, Th1/Th2 ratio reduces.The Th1 hypofunction bring out body immune system can not produce the TC cell of capacity and Th1 cytokines with kill and wound, target cell that break virus infects and suppress duplicating and expressing of viral gene, body can not in time be removed virus; The Th2 cytokines then further suppresses the function of Th1; The lasting stimulation of virus antigen is inducing specific t cell proliferation or incapability again, therefore forms the immunologic tolerance of host to virus antigen, has finally caused the chronic delay of all kinds of viral infection.
Present clinical shortage is specifically designed to the active drug of treatment Th1/Th2 balance disorder.The inventor finds can effectively regulate the disorder of Th1/Th2 balance as the pharmaceutical composition of effective ingredient with foscarnet sodium, also can produce the positive therapeutic effect to above-mentioned viral disease simultaneously, thereby finish the present invention.
Summary of the invention
The purpose of this invention is to provide the Th1/Th2 balance disorder that a kind of purposes, especially chronic HBV (HBV) of anti-Th1/Th2 balance disorder of pharmaceutical composition cause.
Pharmaceutical composition of the present invention comprises foscarnet sodium and medicinal acceptable auxiliary.Wherein the content of foscarnet sodium can be 0.1%-10%, is preferably 0.5%-5.0%, most preferably is 1.0%-3.0%.
Compositions of the present invention can be prepared into the dosage form that is fit to multiple administering mode.Mainly comprise the dosage form that is fit to oral administration and drug administration by injection.Be preferably ejection preparation, most preferably be vein high capacity NaCL injection.
The pharmaceutical preparation that is fit to oral administration is meant that pharmaceutically the regular dosage form of oral administration comprises tablet, powder, granule, capsule, drop pill, oral liquid, pellet etc.Be preferably tablet, capsule, drop pill.Wherein tablet comprises plain sheet, coated tablet, slow releasing tablet, dispersible tablet, enteric coatel tablets, buccal tablet, chewable tablet, effervescent tablet etc.; Capsule comprises hard capsule, soft capsule, slow releasing capsule, enteric coated capsule etc.; Pellet comprises common pellets, slow-release micro-pill, enteric coated micropill, controlled release micro pill etc.Adjuvant can adopt the acceptable conventional adjuvant of pharmacy.Adopt pharmacy conventional formulation mode to prepare.
The preparation of drug administration by injection can utilize foscarnet sodium and sterile carrier to adopt the pharmacy conventional method to be prepared from, and according to required concentration it is dissolved in the carrier.When preparation solution, active component can be dissolved in water for injection and filtration sterilization, be filled into sealing preservation in the container afterwards.Advantageously, can add injection adjuvant such as antiseptic commonly used, buffer agent, acidity-basicity regulator, Osmolyte regulator, solubilizing agent, stabilizing agent, antioxidant etc. in order to be fit to intravenous injection.
The inventor has investigated immune organ and the Th1/Th2 equilibrated influence of Foscarnet sodium composition to the immunologic hypofunction rat model, and it is disorderly and obviously improve the impaired immunologic function of rat to find that Foscarnet sodium composition of the present invention can effectively be regulated rat model Th1/Th2 ratio.Can illustrate that by this experiment Foscarnet sodium composition of the present invention can recover the Th1/Th2 function balance.
By clinical experiment, the pharmaceutical composition that contains foscarnet sodium that the inventor finds to give the patient treatment dose of Th1/Th2 balance disorder can effectively improve the ratio of Th1/Th2.Said composition is remarkable to the disorderly effect of Th1/Th2 balance that each viroid especially hepatitis B virus causes.Particularly has significant curative effect to improving the chronic severe hepatitis B that hepatitis B virus causes and the Th1/Th2 dysfunction of the chronic severe hepatitis B patient of icteric.
Foscarnet sodium described in this description, its chemistry is by name: foscarnet sodium salt hexahydrate or phosphonium mesitoyl formic acid trisodium hexahydrate.
The disorder of the balance of Th1/Th2 described in this description is meant the imbalance of function balance between Th1, the Th2 that a variety of causes causes, and refers in particular to adopt that Th1, Th2 are excretory to have distinctive cytokine as the represented Th1/Th2 dysfunction of index.
The reason of the disorder of the various Th1/Th2 of causing balance described in this description exist multiple may, mainly be meant but and not only refer to especially hepatitis B virus (HBV) such as each viroid such as hepatitis B virus (HBV), hepatitis C virus (HCV), HIV (human immunodeficiency virus) (HIV), cytomegalovirus (CMV), herpes simplex virus (HSV), change of coxsackie b virus (CVB).
The Th1/Th2 balance disorder that the described hepatitis B virus of this description causes especially refers to the Th1/Th2 dysfunction of chronic severe hepatitis B or the chronic severe hepatitis B patient of icteric.
Because the disorder of Th1/Th2 balance is in multiple advancing of disease and lapse to and all played the part of the key player in the process, therefore this medical composition also has the positive therapeutic effect to all kinds of diseases that occur the disorder of Th1/Th2 balance in the pathogenic process, and is especially remarkable to human hepatitis B and therapy for hepatitis C effect.
The inventor describes beneficial effect of the present invention in detail by embodiment 1,2,3.
The specific embodiment
We specify the present invention in conjunction with embodiment.Following examples only are used to technology contents of the present invention is described, are not to be used to limit the scope of the invention.
Embodiment 1 Foscarnet sodium composition is to the equilibrated influence of immunologic hypofunction rat Th1/Th2.
The model preparation: 1 subcutaneous injection acetic acid cortisone 100mg/kg next day of giving male Wistar rat, 14d makes the immunologic hypofunction rat model continuously.
Reagent and experimental technique: IFN-detection kit; The IL-4 detection kit.Method: 50 200g ± 20g of rat,
♀ half and half.Be divided into 5 groups at random: normal group, model group and large, medium and small dosed administration group.Model group and each administration group said method modeling.Modeling begins lumbar injection simultaneously and gives with the volume Foscavir, and dosage is respectively 200mg/kg, 400mg/kg, 800mg/kg, and model group and normal group give the equal volume normal saline.Respectively organize rat after experiment finishes and weigh, the eye socket vein is got blood, puts to death and dissects the spleen calculating spleen index of weighing, and centrifugalize serum is frozen to be equipped with inspection in-20 ℃.The double-antibody sandwich elisa method is adopted in experiment, and concrete operations are carried out to specifications.Measure IFN-γ in each serum specimen, the concentration (pgml of IL-4
-1).Represent Th1 with IFN-γ concentration, IL-4 concentration is represented Th2, thereby calculates the ratio of Th1 and Th2.The results are shown in Table 3,4.
Table 3 Foscavir is to the influence of rat IFN-γ, IL-4 and Th1/Th2
| Group | Dosage | n | IFN-γ | IL-4 | Th1/Th2 |
| Normal group | With volume NS | 10 | 13.7±1.81 | 24.7±4.37 | 0.55±0.14 |
| Model group | With volume NS | 10 | 11.4±2.09 * | 37.0±6.15 *** | 0.31±0.09 *** |
| Heavy dose of group | 800mg/kg | 10 | 13.0±1.33 | 28.6±7.23# | 0.46±0.13# |
| Middle dosage group | 400mg/kg | 10 | 13.3±1.81# | 29.1±7.02# | 0.46±0.14# |
| Small dose group | 200mg/kg | 10 | 13.3±1.59# | 36.3±6.37 *** | 0.37±0.10 ** |
*P＜0.05 is to compare with normal group; #p＜0.05 is to compare with model group.
Table 4 Foscavir is to the influence of rat body weight, spleen weight and spleen index
| Group | Dosage | n | Body weight (g) | Spleen heavy (g) | Spleen index (%) |
| Normal group | With volume NS | 10 | 225.3±17.7 | 0.991±0.36 | 0.44±0.17 |
| Model group | With volume NS | 10 | 185.7±16.2 * | 0.530±0.26 * | 0.28±0.14 * |
| Heavy dose of group | 800mg/kg | 10 | 213.7±26.0# | 0.863±0.21## | 0.40±0.09# |
| Middle dosage group | 400mg/kg | 10 | 211.4±19.5# | 0.786±0.25# | 0.37±0.17# |
| Small dose group | 200mg/kg | 10 | 198.7±19.7 * | 0.640±0.23 * | 0.32±0.11 * |
*P＜0.05 is to compare with normal group; #p＜0.05 is to compare with model group.
Experimental result as can be known, lumbar injection gives immunologic hypofunction rat model Foscavir, can improve rat blood serum IFN-γ concentration, reduces the content of serum il-4 simultaneously, improves Th1/Th2 ratio, the effect of big or middle dosage group is suitable.Immunologic hypofunction model group rat body weight and spleen weight and spleen index all have obvious decline than normal group as shown in Table 4, These parameters is recovered to some extent after giving Foscavir, especially big or middle dosage group spleen index is near normal value, and small dose group also has rising trend but do not have significant difference.
This description of test Foscavir can effectively improve the inductive rat immunity hypofunction of acetic acid cortisone, recovers the dysequilibrium of Th1/Th2.
Embodiment 2
Chronic hepatitis B is light, moderate patient's 25 examples, male's 15 examples, women's 10 examples; Case diagnosis all carries out in JIUYUE, 2000 whole nation viral hepatitis academic conference (Xi'an) " viral hepatitis is prevented and treated scheme " of uniting revision by Chinese Medical Association's infectious disease and parasitic disease credit meeting, hepatopathy credit meeting.To appeal the patient and be divided into matched group and treatment group at random, the treatment group gives Foscavir 3g/ time, and one day twice, continuous 4 weeks.
Reagent and method
Reagent: IFN-detection kit; The IL-4 detection kit.Method: IFN-γ, IL-4 detect and adopt double-antibody sandwich enzyme connection analytic process.Take out required lath from balance to the sealing bag of room temperature, respectively specimen and variable concentrations standard substance (100 μ L/ hole) are added in the respective aperture, and then add biotinylated antibody working solution (50 μ L/ hole) and enzyme conjugates (20～25 ℃) is hatched 120min jointly.Wash plate 3 times, successively add substrate A, each 100 μ L/ hole of B, lucifuge is put room temperature 10～30min.Add stop buffer 50 μ L/ holes, promptly be engraved in behind the mixing and measure the A450 value on the ELISA readout instrument, the drawing standard curve, and measure IFN-γ in each serum specimen, the concentration (ngL of IL-4
-1).Represent Th1 with IFN-γ concentration, IL-4 concentration is represented Th2, thereby calculates the ratio of Th1 and Th2.
Experimental result
Table 1 Foscavir is to the influence of chronic mild or moderate hepatitis B IFN-γ, IL-4 and Th1/Th2
| Group | N | IFN-γ | IL-4 | Th1/Th2 |
| The treatment of control group group | 12 13 | 78.97±16.27 83.90±22.75 | 10.1±3.8 6.7±2.5 * | 8.97±3.73 14.2±5.99 * |
*P＜0.05 is and the matched group ratio.
Experimental result shows that the Foscavir that gives the patient infusion therapeutic dose can obviously improve chronic viral hepatitis B patient's TH1/TH2 ratio, improves patient's TH1/TH2 balance disorder.
Embodiment 3
The chronic severe hepatitis B patient of this The effects is IFN-γ before and after treatment, and IL-4 changes in prediction on such basis Drug therapy to the influence of patient Th1 and Th2 function.Be chosen in whole treatment stage dead chronic severe hepatitis B patient 12 examples (male's 11 examples, women's 1 example) and heavy chronic hepatitis B patient 9 examples (being the male) do not take place.Case diagnosis all carries out in JIUYUE, 2000 whole nation viral hepatitis academic conference (Xi'an) " viral hepatitis is prevented and treated scheme " of uniting revision by Chinese Medical Association's infectious disease and parasitic disease credit meeting, hepatopathy credit meeting.Two groups all give Foscavir 3g/ time on the basis of Comprehensive Treatment, and one day twice, continuous 4 weeks.The ratio that detects treatment front and back patient Th1/Th2 changes.
Reagent and method
Reagent: IFN-detection kit; The IL-4 detection kit.Method: above-mentioned each the venous blood samples 3ml of case patient that respectively organizes, separation of serum is frozen to be equipped with inspection in-20 ℃.The double-antibody sandwich elisa method is adopted in experiment, and concrete operations are carried out to specifications.Measure IFN-γ in each serum specimen, the concentration (pgml of IL-4
-1).Represent Th1 with IFN-γ concentration, IL-4 concentration is represented Th2, thereby calculates the ratio of Th1 and Th2.
Experimental result
Table 2 Foscavir is to the influence of Th1/Th2 before and after chronic severe hepatitis B, the treatment of heavy chronic hepatitis B patient
| Group | n | Before the administration | After the administration | ||||
| IFN-γ | IL-4 | Th1/Th2 | IFN-γ | IL-4 | Th1/Th2 | ||
| Chronic severe hepatitis | 12 | 61.0±25.6 | 7.6±1.81 | 8.9±3.83 | 61.8±20.9 | 5.1±1.43 * | 12.4±3.46 * |
| Heavy hepatitis B | 9 | 95.2±34.4 | 9.2±2.2 | 10.30±2.72 | 101.7±27.3 | 5.6±1.82 * | 20.1±9.3 * |
*P＜0.05 be with administration before corresponding data relatively.
From The above results as can be seen, through the treatment of Foscavir, IFN-γ changes before and after two groups of patient's administrations does not have significant difference, and IL-4 significantly reduces after the administration, and Th1/Th2 obviously raises.Show that Foscavir can obviously improve the Th1/Th2 balance disorder of chronic severe hepatitis B and heavy chronic hepatitis B patient.
Claims (9)
1, a kind of is the purposes of pharmaceutical composition in the medicine of preparation treatment Th1/Th2 balance disorder of active component with the foscarnet sodium.
2, the described purposes of claim 1, wherein the disorder of Th1/Th2 balance is meant the Th1/Th2 balance disorder that each viroid causes.
3, the described purposes of claim 2, wherein the Th1/Th2 balance disorder that causes of each viroid is meant the Th1/Th2 balance disorder that hepatitis B virus causes.
4, the described purposes of claim 3, wherein the Th1/Th2 balance disorder that causes of hepatitis B virus is meant the Th1/Th2 dysfunction of chronic severe hepatitis B or the chronic severe hepatitis B patient of icteric.
5, purposes according to claim 1, wherein compositions is an injection.
6, the described purposes of claim 5, wherein said injection are high capacity NaCL injection.
7, the arbitrary described purposes of claim 1-6 wherein is the 0.1-10% that foscarnet sodium accounts for the compositions gross mass in the pharmaceutical composition of active component with the foscarnet sodium.
8, the arbitrary described purposes of claim 1-6 wherein is the 0.5-5.0% that foscarnet sodium accounts for the compositions gross mass in the pharmaceutical composition of active component with the foscarnet sodium.
9, the arbitrary described purposes of claim 1-6 wherein is the 1.0-3.0% that foscarnet sodium accounts for the compositions gross mass in the pharmaceutical composition of active component with the foscarnet sodium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100972812A CN100464753C (en) | 2006-10-27 | 2006-10-27 | foscarnet sodium composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100972812A CN100464753C (en) | 2006-10-27 | 2006-10-27 | foscarnet sodium composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1943582A true CN1943582A (en) | 2007-04-11 |
| CN100464753C CN100464753C (en) | 2009-03-04 |
Family
ID=38043376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100972812A Active CN100464753C (en) | 2006-10-27 | 2006-10-27 | foscarnet sodium composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100464753C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021203706A1 (en) * | 2020-04-07 | 2021-10-14 | 中国科学院深圳先进技术研究院 | Use of foscarnet sodium in preparation of medicines for preventing and treating coronaviruses |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153334A1 (en) * | 2021-01-15 | 2022-07-21 | Jubilant Generics Ltd | Transmucosal dosage forms of foscarnet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591889A (en) * | 1991-03-06 | 1997-01-07 | Aktiebolaget Astra | Method for the synthesis of trisodium phosphonoformate hexahydrate |
| CN1433764A (en) * | 2003-02-28 | 2003-08-06 | 蔡惠明 | Sodium foscarnet gel preparation and preparation process thereof |
| CN1186025C (en) * | 2003-02-28 | 2005-01-26 | 蔡惠明 | Sodium foscarnet froozen dry preparation and process for preparing same |
-
2006
- 2006-10-27 CN CNB2006100972812A patent/CN100464753C/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021203706A1 (en) * | 2020-04-07 | 2021-10-14 | 中国科学院深圳先进技术研究院 | Use of foscarnet sodium in preparation of medicines for preventing and treating coronaviruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100464753C (en) | 2009-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1111414C (en) | Pharmaceutical use of magnesium salts or magnesium complexes | |
| CN111265500A (en) | Pharmaceutical composition for preventing and treating COVID-19 and preparation method thereof | |
| CN100464753C (en) | foscarnet sodium composition | |
| Chiou et al. | The extract of Cordyceps sinensis inhibited airway inflammation by blocking NF-κB activity | |
| CN1846705A (en) | Application of glycyrrhizic acid and glycyrrhetic acid in preparing medicine for inflammatory enteropathy | |
| CN101961454A (en) | Application of resina draconis to preparing compound enema for treating ulcerative colitis | |
| CN115089590B (en) | Application of cyclopentyl triazolopyrimidine as pharmaceutical ingredient in hepatitis drugs | |
| CN1251681C (en) | Highly concentration water-soluble vitamin for intravenous injection and preparation and use | |
| CZ20012519A3 (en) | Nucleoside intended for use as a medicament for treating immunity system response in exposition | |
| CN1522759A (en) | Interferon and synergist combined pharmaceutical | |
| CN1299676C (en) | Anti-anoxia medicinal composition | |
| CN1225249C (en) | Antivirus medicine for raising immunity and its preaparation method | |
| CN1457880A (en) | Polyresistin dripping pill and its preparing method for immunodeficiency | |
| CN1138572A (en) | Application of Ubimec medicinal compsn. or containing ubimec for treatment virus hepatitis | |
| RU2359664C1 (en) | Pharmaceutical injection composition on basis of tilorone for treatment of purulent-destructive processes with signs of immune insufficiency | |
| RU2364390C1 (en) | Pharmaceutical injection tilorone-based composition for treatment of diseases with immunodeficiency signs | |
| CN111529516B (en) | Application of spermidine in preparation of anti-hepatitis B virus drugs | |
| CN111281893B (en) | Application of mycobacterium vaccae for injection in preparation of medicament for preventing and treating COVID-19 | |
| CN1889976A (en) | Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof | |
| CN1232302C (en) | Compound preparation of Azithromycin and Pidotimod | |
| CN117281800A (en) | Application of niclosamide in preparing medicine for treating hepatitis B | |
| CN1238053C (en) | Medicine composition containing alfa-interferon , lamivudine and adefovir | |
| CN1275646C (en) | Nose drops of recombined human interferon alpha 2b and preparing method | |
| CN118924745A (en) | Use of olmesartan medoxomil single drug and sorafenib combination therapy in preventing/treating diabetes | |
| RU2518277C2 (en) | Method of treating influenza and influenza-like illnesses complicated with pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: JIANGSU CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Shen Jun Document name: Notification of Passing Examination on Formalities |
|
| CP03 | Change of name, title or address |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Country or region after: China Address before: 222006 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Country or region before: China |
|
| CP03 | Change of name, title or address |